Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Towa’s Shipment Restriction List Now Expands to 352 Products
Big 3 generic player Towa Pharmaceutical has now seen its list of drugs subject to adjusted shipments grow to 352 products as spillover effects from industry peers continue. The company said on August 11 that it newly added 64 products…
To read the full story
Related Article
- Sawai Now Curbing Shipments for 432 Products
September 24, 2021
- Towa’s Shipment Restriction List Now Expands to 385 Products
September 24, 2021
- Sawai’s Shipment Curbs Now Affect 414 Products
August 20, 2021
- Towa’s Shipment Curbs Now Affect 319 Products, Active Vitamin Analogs Too
July 29, 2021
- Sawai’s Shipment Restrictions Now Reaches 385 Products
July 20, 2021
- Towa’s Shipment Control List Expands to 241 Products; 7 Added
July 13, 2021
- Towa Now Curbs Shipments for 235 Products; 27 Added to Restriction List
July 2, 2021
- Sawai Expands Shipment Adjustments to 369 Products
June 28, 2021
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…